Skip to main content


High Dose Anakinra Effective in COVID-19

Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs. 56% ;p=0·009) and greater improvements in CRP and pulmonary function (72% vs 50%) compared to controls at day 21.

The Nine Lives of Hydroxychloroquine (Updated)

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory arthropathy.

RheumNow Podcast - COVID Kids and Men (5.15.20)

Dr. Jack Cush reviews the news and journal articles from the past week on

CDC on Pediatric Multi-System Inflammatory Syndrome

The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.

Kids' COVID-Linked Ailment Is Not Your Typical Kawasaki Disease

As data continue to emerge about a multi-system inflammatory disorder in children apparently connected to COVID-19, evidence is growing that this is not your typical Kawasaki disease.

Plaquenil Does Not Protect Lupus Patients from COVID-19

Annals of Rheumatic Disease reports on an analysis of lupus (SLE) patients that shows COVID-19 infection rates were similar between those lupus patients who were taking hydroxychloroquine (HCQ) and those not taking HCQ. 

TNR Grand Rounds - What does COVID-19 have to do with Lupus?

Last night's Tuesday Nite Rheumatology featured Dr. Joan Merrill (OMRF). In her lecture, "What does COVID-19 have to do with lupus?", she discusses the pathogenesis of lupus, and specifically thrombotic microangiopathy, complementopathies, catastrophic lupus syndrome and the potential overlap with the vascular pathology seen with COVID-19 infection.

God Bless Nurses

It's Nurses Week and time to reaffirm our reverence for nurses. Dr. Jack Cush gives a video testimonial to the dedication, dependability and excellence Nurses bring to patient care. God Bless our Nurses! 

Risk of COVID-19 at Choir Practice

MMWR reports that after attending a 2.5 hr choir practice with one COVID+ symptomatic person, 87% of the choir developed COVID 19; 3 were hospitalized, and two died. 

New ACR Guidelines for Gout Management

The ACR has published the 2020 guidelines on the management of gout that includes strong recommendations favoring treat‐to‐target management and starting urate lowering therapy (ULT) for patients with frequent flares, radiographic damage or tophi due to gout.

Secukinumab Better than Adalimumab - Maybe?

The EXCEED study was a head-to-head trial of secukinumab (SEC) versus adalimumab (ADA) as first-line monotherapy in psoriatic arthritis (PsA) patients; this 52 week trial showed that while SEC failed to achieve clinical superiority over ADA, SEC treated patients demonstrated higher treat

RheumNow Podcast – The Beat Goes On (5.8.20)

Dr. Jack Cush reviews the news and journal reports from the past week on